News | August 11, 2024
HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
Our centers are performing as expected or even better
Our centers are performing as expected or even better
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
The inspection was concluded with two 483 observations
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The inspections concluded with no Form 483 observations or significant critical findings
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Subscribe To Our Newsletter & Stay Updated
